The purpose of the present study is to evaluate the efficacy of the preconditioned autologous bone marrow mesenchymal stem cells for patients with ischemic heart diseases.

Inclusion Criteria:

• Age under 75;
• Clinical diagnosis of acute Myocardial Infarction, chronic Myocardial Infarction and Ischemic Cardiomyopathy
• NYHA (New York Heart Association) grade: III-IV, LVEF (left ventricular ejection fraction): 25-50%;
• No infection diseases including HBV (hepatitis B virus), HCV (hepatitis C virus ), syphilis and AIDS;
• No psychiatric illnesses and speaking dysfunction;
• Informed consent.

Exclusion Criteria:

• More than 75 years old;
• LVEF<24%;
• Unstable hemodynamics, shock;
• Severe infection;
• Patients have tumor or other lethal diseases (expectation of life<6 months);
• Radiation patients;
• hematopoietic malignancy including Haemophiliacs;
• Anemia (Hb<100g/L);
• The other clinical trial participants within one month;
• Abnormal increasing of the blood biochemical indicators that is not explained by the conditions;
• Informed refusal.